Dr. Karam on the Use of Laparoscopy in Advanced Ovarian Cancer

Video

Amer Karam, MD, associate clinical professor of Gynecologic Oncology at Stanford Hospital and director of Robotic Surgery and Outreach in the Division of Gynecologic Oncology at Stanford Medicine, discusses the use of laparoscopy in advanced ovarian cancer.

Amer Karam, MD, associate clinical professor of Gynecologic Oncology at Stanford Hospital and director of Robotic Surgery and Outreach in the Division of Gynecologic Oncology at Stanford Medicine, discusses the use of laparoscopy in advanced ovarian cancer.

Any patient who comes to the clinic with advanced-stage ovarian cancer should be offered laparoscopy as a way to triage them for primary debulking surgery, says Karam. It is something that is universally applied to all of Karam’s patients prior to undergoing primary debulking surgery.

Physicians may approach borderline tumors differently, explains Karam, as the rate of advanced-stage borderline tumors is lower than is expected in high-grade ovarian cancer, as such, physicians have a higher likelihood of finding early-stage disease with these tumors.

If a patient presents with a borderline tumor, diagnostic laparoscopy can still be useful, he adds, as there are situations in which borderline tumors are spread so far inside the abdomen that surgery would not be able to resect all of the disease. For these patients, there may be a role for surgical debulking, even if they’re not left with minimal residual disease, concludes Karam.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology